产品
编 号：F749962
分子量：146000
分子量：146000
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2226212-40-2
产品详情
生物活性：
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.
体内研究：
Talquetamab (JNJ-64407564) (0.1-50 μg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性。Animal Model:Female NSG mice with H929 cells
Dosage:0.1-10 μg (0.005 mg/kg)
Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:Completely blocked tumor formation at 1 μg and 10 μg doses.
Animal Model:Female NSG mice with human MM cells
Dosage:0.1-50 μg (0.005 mg/kg)
Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.
体外研究：
Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD4+ 和CD8+ T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加.
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.
体内研究：
Talquetamab (JNJ-64407564) (0.1-50 μg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性。Animal Model:Female NSG mice with H929 cells
Dosage:0.1-10 μg (0.005 mg/kg)
Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:Completely blocked tumor formation at 1 μg and 10 μg doses.
Animal Model:Female NSG mice with human MM cells
Dosage:0.1-50 μg (0.005 mg/kg)
Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.
体外研究：
Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD4+ 和CD8+ T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备